RiteMED Ciprofloxacin Adverse Reactions

Frequently reported adverse events, drug related or not, were nausea (5.2%), diarrhea (2.3%), abdominal pain/discomfort (1.7%), headache (1.2%), restlessness (1.1%) and rash (1.1%).
Additional events which occurred in less than 1% of ciprofloxacin patients include the following: Central nervous system: dizziness, lightheadedness, insomnia, nightmares, hallucinations, manic reaction, irritability, tremor, ataxia, convulsive seizures, lethargy, drowsiness, weakness, malaise, anorexia, phobia, depersonalization, depression, paresthesia.
Cardiovascular: palpitation, atrial flutter, ventricular ectopy, syncope, hypertension, angina pectoris, myocardial infarction, cardiopulmonary arrest, cerebral thrombosis.
Respiratory: dyspnea, epistaxis, laryngeal or pulmonary edema, hiccough, hemoptysis, bronchospasm, pulmonary embolism.
Gastrointestinal: painful oral mucosa, oral candidiasis, dysphagia, intestinal perforation, gastrointestinal bleeding. Cholestatic jaundice has been reported.
Skin/hypersensitivity: pruritus, urticaria, photosensitivity, flushing, fever, chills, angioedema, edema of the face, neck, lips, conjunctivae or hands, cutaneous candidiasis, hyperpigmentation, erythema nodosum. Allergic reactions ranging from urticaria to anaphylactic reactions have also been reported.
Renal/urogenital: interstitial nephritis, nephritis, renal failure, polyuria, urinary retention, urethral bleeding, vaginitis, acidosis, breast pain.
Musculoskeletal: arthralgia, or back pain, joint stiffness, achiness, neck or chest pain, flare up of gout.
Hemic/lymphatic: lymphadenopathy.
Special senses: blurred vision, disturbed vision (change in color perception, overbrightness of lights), decreased visual acuity, diplopia, eye pain, tinnitus, hearing loss, bad taste.
Adverse Laboratory Changes: Changes in laboratory parameters listed as adverse events without regard to drug relationship are as follows: Hepatic: elevations of ALT (1.9%), AST (1.7%), alkaline phosphatase (0.8%), LDH (0.4%), serum bilirubin (0.3%).
Hematologic: eosinophilia (0.6%), leucopenia (0.4%), decreased blood platelets (0.1%), elevated blood platelets (0.1%), pancytopenia (0.1%).
Renal: elevations of serum creatinine (1.1%), BUN (0.9%), crystalluria, cylinduria, and hematuria have been reported.
Other changes reported in less than 0.1% of patients were: elevation of serum gammaglutamyl transferase, elevation of serum amylase, reduction in blood glucose, elevated uric acid, decrease in hemoglobin, anemia, bleeding diathesis, increase in blood monocytes, and leukocytosis.